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Introduction. Partial nephrectomy (PN) is playing an increasingly important role in localized renal cell carcinoma (RCC) as a
true alternative to radical nephrectomy. With the greater experience and expertise of surgical teams, it has become an alternative
to radical nephrectomy in young patients when the tumor diameter is 4 cm or less in almost all hospitals since cancer-speciﬁc
survival outcomes are similar to those obtained with radical nephrectomy. Materials and Methods. The authors comment on
their own experience and review the literature, reporting current indications and outcomes including complications. The surgical
technique of open partial nephrectomy is outlined. Conclusions. Nowadays, open PN is the gold standard technique to treat small
renal masses, and all nonablative techniques must pass the test of time to be compared to PN. It is not ethical for patients to
undergo radical surgery just because the urologists involved do not have adequate experience with PN. Patients should be involved
in the ﬁnal treatment decision and, when appropriate, referred to specialized centers with experience in open or laparoscopic
partial nephrectomies.
Copyright © 2008 J. M. Cozar and M. Tallada. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
In recent years, the surgical treatment of renal cell carcinoma
(RCC) has developed towards conservative surgery of the
renal parenchyma and the use of minimally invasive tech-
niques. The emerging conservative technique is open partial
nephrectomy(PN),whichisnolongeranoptionreservedfor
patients with a single kidney or bilateral renal tumors; it has
become a viable alternative to radical nephrectomy, and is
considered the treatment of choice for selected patients with
a normal contralateral kidney [1, 2].
The more frequent use of PN in renal cancer treatment
derives from a spectacular rise in the incidental diagnosis of
renal tumors in patients undergoing abdominal ultrasound
or computed tomography (CT) for abdominal diseases. This
has markedly increased the detection of smaller, asymp-
tomatic tumors than those observed when Robson proposed
radical nephrectomy as the technique of choice more than
three decades ago [3]. Incidental tumors have a more
favorable prognosis than clinically detected or symptomatic
tumorsofasimilarsizeandstage[4,5].Thebetterhealthand
longer life span of the general population and the availability
of radiological imaging techniques for closer screening and
follow-up programs are creating a favorable environment for
the development of conservative renal surgery. When PN
is indicated, the decision to adopt an open or laparoscopic
(minimally invasive) approach depends on the beneﬁts and
risks to the patient and the experience of the surgical team.
This article is devoted to open PN, providing an
update on the indications, disease-free and disease-speciﬁc
survival outcomes, beneﬁts and risks, limitations and
technical aspects of the surgery, intra- and postoperative
complications, and post-treatment follow-up protocols. The
aim is to describe the main concepts to be considered in the
decision-taking algorithm for an open PN in the treatment
of RCC [6, 7].
2. INDICATIONS FOR PARTIAL NEPHRECTOMY
Indications can be classiﬁed as absolute, relative, or elective
(Algorithm 1), always basing the selection on the viability of
the technique and an optimal cancer control [8].
2.1. Absoluteindications
Absolute indications relate to patients who would be
anatomicallyorfunctionallyanephricifradicalnephrectomy2 Advances in Urology
(1) Absolute
(i) Single kidney
(ii) Bilateral renal tumor
(iii) Severe renal failure
(2) Relative
(i) Abnormal contralateral kidney (nephropathy,
nephrolithiasis, trauma, etc.)
(ii) Metabolic disease associated with renal failure
(iii) Genetic syndrome with tumor multifocality
(e.g., VHL syndrome)
(3) Elective
(i) Tumor <4cm in young and healthy patients
(ii) Peripheral tumor
(iii) Tumor >4cm(limitat7cm?)
Algorithm 1: Indications for partial nephrectomy.
was performed. They include the presence of only one
kidney, synchronous bilateral renal cancer, and severe renal
failure. It was proposed in the 1950’s that these patients
undergo conservative tumor excision to preserve maximum
renal parenchyma and allow the possibility of renal ﬁltration
with no need for dialysis. However, this proposal gained
little acceptance among urologists due to the high rate of
complications observed after open PN. More recently, there
hasbeenastrongresurgenceintheuseofthistechniqueasan
alternative to radical nephrectomy for the above-mentioned
types of patients. In the 1990’s, various studies reported
good survival outcomes and fewer complications with a
conservative approach.
2.2. Relativeindications
These include conditions that might compromise the future
functioning of the contralateral kidney (without tumor),
for example, moderate renal failure, nephrolithiasis, recur-
rent pyelonephritis with parenchymal lesions, vesicoureteral
reﬂux, and congenital or acquired obstruction of the urinary
tract, among others. A further relative indication would be
the presence of disease with a potentially negative medium-
term eﬀect on renal function, for example, diabetes or
hypertension. Other factors must be taken into account in
these patients, including their current age and age at onset of
the disease, estimating the duration of its possible eﬀect on
renal function.
2.3. Electiveindications
Partial nephrectomy has been proposed for small peripheral
renal tumors over the past few years. Being initially
controversial, this indication has been supported by wide
studies showing similar outcomes to radical surgery in
small (≤4 c m )r e n a lt u m o r s( Algorithm 1). The age and
general state of the patient are important in the selection
of candidates for PN, which is most beneﬁcial for young
and healthy patients. Some authors have proposed to widen
the indication for a conservative approach to include larger
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Figure 1: Five-year survival: radical nephrectomy (RN) versus
partial nephrectomy (PN).
tumors of up to 7cm. Thus, Fergany et al. at the Cleveland
Clinic reported similar ﬁve-year disease-free survival rates
between patients with tumors <4cm and those with tumors
of 4–7cm [4].
The greater longevity of the population and the treat-
ment of ever younger patients for incidentally detected
tumors have drawn attention to the long-term risks of renal
failure or metachronous tumor recurrence posed by PN
treatment. Nevertheless, these risks should not outweigh the
beneﬁts of this renal parenchyma-preserving surgery.
3. CLINICAL EXPERIENCE: SURVIVAL OUTCOMES
Thereisnowconsiderableclinicalexperienceinpatientswith
one of the above indications for PN, allowing careful analysis
of patient outcomes and evaluation of the prognostic factors
that inﬂuence results.
Studies of patients with small renal tumors at the
Memorial Sloan Kettering Cancer Center of UCLA, Mayo
Clinic, and Cleveland Clinic showed no signiﬁcant diﬀer-
ences in ﬁve-year survival rates (91–100%) between those
treated with open PN and those treated with open radical
nephrectomy (Figure 1)[ 9–14]. Long-term follow-up stud-
ieshavecorroboratedtheseresults.Thus,Lauetal.compared
between patients treated with open PN (mean tumor size of
3.7cm) and those treated with radical nephrectomy (mean
sizeof3.3cm),andfoundnosigniﬁcantdiﬀerencesinoverall
survival, cancer-speciﬁc survival, metastasis-free survival, or
local recurrence-free survival at 5, 10, or 15 years [11]. These
ﬁndings validate the oncological eﬃcacy of conservative
versus radical renal surgery.
Therehavebeennoprospectiverandomizedclinicaltrials
comparing the two techniques. Moreover, global results of
the published studies cannot be grouped together because
the distribution of indication levels (absolute, relative, or
elective)isdiﬀerentineachstudypopulation.Forthisreason,J. M. Cozar and M. Tallada 3
Table 1: Conservative renal surgery (partial nephrectomy); ﬁve-year outcomes in patients with elective indication.
Author, year N Disease-speciﬁc survival Local recurrence Mean tumor size
Morgan, 1990 20 100% 0% 3.1
Selli, 1991 20 90% 0% 3.5
Provet, 1991 19 100% 0% 2.6
Steinbach, 1992 72 94.4% 2.7% ND
Moll, 1993 98 100% 1% 4
Lerner, 1996 54 92% 5.6% 4
D’Armiento, 1997 19 96% 0% 3.3
Van Poppel, 1998 51 98% 0% 3
Herr, 1999 70 97.5% 1.5% 3
Hafez, 1999 45 100% 0% 4
Barbalias, 1999 41 97.5% 7.3% 3.5
Belldegrun, 1999 63 100% 3.2% 4
outcomes of open PN are reported below in relation to the
type of indication.
3.1. Outcomesofpartialnephrectomywith
absoluteindication
In general terms, patient survival rates are lower when
the indication for surgery is absolute rather than elective,
inﬂuenced by the higher age, the more advanced stages, the
larger tumor size, and the poorer health status of patients
with an absolute indication. Reports from the Cleveland
and Mayo Clinics [4, 15] described disease-free survival
rates after PN of 81–88% at 5 years and 64–73% at 10
years, being relatively similar to disease-free survival rates
described for radical nephrectomy in tumors of the same
size and stage. In 2007, Berdjis et al. studied 38 cases of open
PN in single kidney carried out between 1993 and 2003
[16]. After a mean follow-up of 41.7 months, they observed
local recurrence in four patients (including 3 with distant
progression) and metastatic progression in two. Tumor
size was signiﬁcantly larger in patients with metastatic
progression versus those without (6.2cm versus 3.5cm)
and in patients with subsequent renal failure versus those
without (5.2cm versus 3.3cm).
According to these authors, tumor size is the most
signiﬁcant prognostic factor for disease progression followed
by tumor stage (localized versus locally advanced), and
larger tumor size is the main prognostic factor for renal
failure onset [16].
3.2. Resultsofpartialnephrectomywith
electiveindication
In the 1990’s, numerous reports [5, 10, 11, 17–26]w e r e
publishedonatotalof572patientswithnormalcontralateral
kidney treated by open PN, having tumor sizes ranging from
2t o4 . 3 c m( Table 1). A survival rate of 90–100% was
achieved in these cases, with a local recurrence rate of 0% in
most series [10, 11, 18–20, 22–25, 27], 1% in 2 series [5, 22],
3 %i n2s e r i e s[ 12, 21] ,a n d6 - 7 %i n2s e r i e s[ 13, 26]. These
outcomes opened up the way for open PN to become an
eﬀective alternative to radical nephrectomy although higher
rates of intra- and postoperative complications were initially
observed.
Published data establish 4cm as the cut-oﬀ tumor size
for indication of this surgery, describing a shorter disease-
free survival period in patients with larger tumors. Studies
report 95% ﬁve-year disease-free survival rates in patients
with a tumor <4cm, comparable to the outcomes of radical
nephrectomy in tumors of a similar size (Table 1).
3.3. Resultsofpartialnephrectomyinpatientswith
VonHippelLindau(VHL)syndrome
The risk of local recurrence is very high in VHL patients
because of the multifocal nature of their malignant tumors;
consequently their disease-free survival is much lower in
comparison to patients with incidental or sporadic renal
carcinoma.
Out of nine VHL patients with bilateral renal carcinoma
studied by Novick and Campbell, seven had local recurrence
andonediedfrommetastaticdisease[2].Itislikelythatmost
of these recurrences represented a manifestation of a micro-
scopic residual CCR that was not excised during the NP [2].
Walther et al. [27] reported on 52 VHL patients with
renal cancer treated at the National Cancer Institute, ﬁnding
that no patient with tumors <3cm developed metastatic
disease. They therefore recommend waiting until this type of
tumor reaches 3cm in order to reduce the need for surgery
before onset of the multiple recurrences observed during
follow-up of these patients.
The eﬀectiveness of PN as a valid alternative for the
treatment of this disease was demonstrated by a multicenter
study in USA on the results of treating 65 patients with
VHL and localized RCC (54 bilateral, 11 unilateral). PN was
performed on 49 of these patients, with ﬁve-year and ten-
year survival rates of 100% and 81%, respectively. These
survival outcomes are similar to those obtained with radical
nephrectomy, and they support the role of PN in the
treatment of this type of patient.
In patients with advanced VHL and large multiple
bilateral tumors that require complete excision of both
kidneys at ﬁrst surgery or after various interventions due
to the post-PN growth of residual RCCs, renal transplant is4 Advances in Urology
an appropriate option to avoid terminal kidney failure and
the need for dialysis, especially in young patients with this
genetic syndrome.
4. PROGNOSTIC FACTORS FOR TUMOR RECURRENCE
AFTER PARTIAL NEPHRECTOMY
In RCC, prognostic factors for distant recurrence or
metastatic progression after radical nephrectomy are known
to include the Fuhrman grade, size, and stage, as well as
histologicaltypeofthetumor,thepresenceofpositivelymph
nodes, and ECOG performance status [2, 8]. Some of these
factors, described below, are of special interest in selecting
candidates for PN.
4.1. Tumorsize>4cm
Tumor size was found to be the most signiﬁcant predictor
of the outcome in large series of PN patients [4, 11, 13, 25].
Tumor size independently predicts local recurrence and is
the most important criterion for the indication of a PN.
The Cleveland Clinic series of 485 PNs, including 9% with
elective indications, showed signiﬁcant diﬀerences in ﬁve-
yearandten-yearsurvivalratesbetweenpatientswithtumors
smaller and larger than 4cm, with a signiﬁcant correlation
between recurrence rate and tumor size. For this reason,
Barbalias et al. [25] proposed a subclassiﬁcation of stage T1
(tumors <7cm and limited to renal parenchyma) into T1a
and T1b for tumor sizes of <4cmand≥4cm, respectively.
Lerneretal.[13]observeda95%ﬁve-yearsurvivalratein
PN patients with tumors <3cm versus an 80% rate in those
with tumors >6cm. They also reported a signiﬁcantly higher
disease-free survival rate in patients with tumors >4cmafter
radical versus partial nephrectomy. More recently, various
studies[9–14,23](Figure 2)demonstratedequivalentcancer
control rates between patients with tumors <4cm and those
with tumors of 4–7cm after electively indicated PN.
4.2. Localizationoftumor
It was classically thought that centrally localized tumors
carried a greater risk of metastasis at the time of disease
presentation. It was therefore considered that the risk of
recurrence and/or progression would be higher after partial
versus radical nephrectomy in central tumors. This idea
was challenged by the results of a retrospective study
by D’Armiento et al. [23] on tumor localization as an
independent risk factor. They found no diﬀerence in cancer-
free survival or recurrence between peripheral tumors (not
extending into the interior of the kidney) and central tumors
(inﬁltrating beyond the renal medulla). These authors
concluded that PN is more complex in the case of central
tumors, but it is not associated with a worse recurrence or
progression prognosis.
4.3. Multifocality
The incidence of small renal tumors removed during radical
nephrectomy for RCC or in necropsies ranges from 4 to 25%
[27, 28]. As a consequence, many urologists have argued
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Figure 2: Five-year disease-free survival by tumor size in patients
undergoing partial nephrectomy.
against PN as a standard treatment for RCC, even when
tumors are small, due to the high risk of multifocality. We
need to know the factors that increase the risk of multifocal-
ity to allow us to select PN when the risk of multifocality is
low and radical nephrectomy when the risk is high.
The main factor signaling an increased risk of multifo-
cality is large tumor size, since 91% of multifocal tumors
are associated with primary tumors >5cm[29]. The second
factoristumorstage(pT2orhigher).Thus,stagepT3ashows
a 16.4% incidence of multifocality, with a mean distance
between primary and secondary tumors of 26.4mm [30].
Other factors increasing the risk of multifocality cannot
be known before surgery but only after examination of
the surgical specimen, including histological factors such
as vascular inﬁltration and papillary or mixed histological
variants [27]. Knowledge of factors carrying an elevated risk
of multifocality alerts to the need for more rigorous patient
follow-upandinspectionofthewholedefattedkidneytorule
out satellite tumors during PN.
With regard to the preoperative detection of multifocal
lesions by imaging techniques, only 22.9% of additional
tumors subsequently observed in specimens after radical
nephrectomy had been detected by ultrasound or CT [31].
Intraoperative ultrasound studies show a higher sensitivity,
detectingupto78%ofmultifocaltumors,whichmaybevery
useful when there are multifocality risk factors and a PN has
been proposed to the patient.
4.4. HighFuhrmannucleargradeandsymptomatic
clinicalpresentation
It was reported that recurrence-free survival after PN was
not only signiﬁcantly improved by smaller tumor size (<4)J. M. Cozar and M. Tallada 5
but also by low Fuhrman grade and incidental clinical
presentation [4]. This ﬁnding was conﬁrmed by Licht [32],
who observed a signiﬁcantly worse prognosis after this
surgery in symptomatic (83% ﬁve-year survival) versus
incidental (94% ﬁve-year survival) tumors.
Moll et al. [5] and Ghavamian et al. [15] reported that
tumor stage and nuclear grade are signiﬁcantly associated
with RCC mortality. These classic prognostic factors are
valid for both radical and partial nephrectomies, but a much
more rigorous follow-up is required if partial nephrectomy is
selected and the pathology study reports grade III disease.
4.5. Surgicalmargins
Conventional PN includes ≥1cm margin of healthy
parenchyma, whereas this margin is not left in tumor
enucleation and there is a higher risk of surgical margin
involvement. Recent reports have shown similar rates of
cancer control between PN and enucleation, provided that
surgical margins in enucleation are examined by intraopera-
tive biopsy of the kidney bed.
In a series of 44 patients treated with PN for tumors
with a mean size of 3.2cm and a mean surgical margin of
2.5mm, 93% had negative surgical margins and showed no
local recurrence after a mean follow-up of 4 years [33]. In
the Mayo Clinic series, all partial nephrectomies were carried
out with margins ≥3mm of healthy peritumoral renal tissue,
veriﬁed by intraoperative biopsy of the kidney bed. Local
ﬁve-year recurrence-free survival was 97% in a series of 130
patients [34].
It can therefore be proposed that a margin of 1-2cm is
not necessary in PN, for which a few millimeters (3–5mm)
can be adequate as long as the intraoperative biopsy of the
kidney bed is negative.
5. SURGICAL TECHNIQUE IN PARTIAL NEPHRECTOMY
Surgical technique in PN has advanced over recent years,
oﬀering improved cancer control and anatomical-functional
outcomes for the saved kidney.
A ﬂankincision approachis used, opening Gerota’s fascia
and localizing the kidney and the tumor. A thorough visual
inspection is essential for adequate planning of the resection,
especially if the tumor is near the hilum. It is controversial
whether renal ischemia is required for the resection. This
decision depends on the nature of the tumor and the skill
of the surgeon. At our center, where there is considerable
experience acquired over many years and excellent cancer
controlandrenalpreservationoutcomeshavebeenobtained,
the renal pedicle is identiﬁed and released, isolating the main
renal artery and vein with vessel-loops.
If the tumor is small and the indication is elective, resec-
tion of the tumor then commences, allowing a safety margin
of several millimeters of healthy renal parenchyma. If there is
no major bleeding as the resection proceeds, total resection
of the tumor is completed without recourse to any type of
renal ischemia. If there is any doubt about the resection
margins after removal of the tumor, an intraoperative biopsy
of the bed is performed and we proceed according to the
Figure 3: Open partial nephrectomy for renal cell carcinoma
of inferior pole satisfactory hemostasis with application of a
ﬁbrinogen hemostatic patch (Tachosil, Nycomed Pharma, Austria).
results. Then, hemostasis of the tumor bed is started rapidly
with single stitches of 4/0vicryl at the main bleeding points
usingspray-coagulationonsecondaryvesselswithanelectric
scalpel, which takes considerable time. To reduce this time,
a technique modiﬁcation was introduced at our centre one
year ago, with the application of a ﬁbrinogen hemostatic
patch (Tachosil, Nycomed Pharma, Austria) on the resection
surface after suturing the main bleeding vessels. This has
shortened the time for intervention and hemostasis to 15–20
minutes, and improved the visual appearance (Figure 3). We
also leave the surgical bed open after the resection, without
usingamattressstitchtodrawtherenalparenchymatogether
for better hemostasis. The resection bed must be carefully
inspected, and the opening of the urinary passage (calyx or
p e l v i s )m u s tb ea v o i d e do r ,w h e nn e c e s s a r y ,r e p a i r e d .
When tumors are large but PN is relatively or absolutely
indicated, we prefer to clamp the renal artery to produce
ischemia after administering intravenous mannitol, keeping
the renal vein patent to minimize the risk of postoperative
acute tubular necrosis. It may also be necessary to clamp
the renal artery in cases of central tumors that aﬀect major
vessels (e.g., arcuate arteries) or in cases of unexpected
bleeding that can only be controlled by ischemia. In these
cases, it is very useful to have the renal pedicle prepared
in advance, allowing ischemia to be produced within a few
seconds and minimizing blood loss.
Intraoperative ultrasonography is not a standard proce-
dure in our setting but can greatly assist in the identiﬁcation
of other renal tumors when multifocality is suspected. Some
authors use intraoperative ultrasonography to demarcate
intrarenal tumors and to avoid damaging large vessels near
the resection line or bed.
Once hemostasis has been achieved, a careful
examination is required to detect any inadvertent opening
of the urinary tract, thereby avoiding postoperative leaks
or ﬁstulas. If an opening is identiﬁed, it is closed using
a resorbable suture. When an opening is suspected but
cannot be seen, an intrapelvic injection of methylene blue is
required, leading some authors to previously insert a ureteral
stent in patients with central-located tumors. Fibrin sealants,6 Advances in Urology
Table 2: Complications after open partial nephrectomy.
Author, year (Hospital) N Acute renal failure (%) Urinary ﬁstula (%)
Ghavamian, 2002 (Mayo Clinic) 63 12.7 3.2
Duque, 1998 (Brigham) 64 15.1 9.1
Polascik, 1995 (Johns Hopkins) 67 1.5 9
Herr, 1994 (Memorial Sloan-KCC) 41 0 0
Campbell, 1994 (Cleveland Clinic) 259 12.7 17.3
as well as being hemostatic agents, can reinforce repair of
the collecting system. Gelfoam soaked with thrombin can
be placed over the defect and then inﬁltrated with Hemaseel
ﬁbrin sealant to close small defects of the urinary tract at the
level of the calyces.
6. COMPLICATIONS OF OPEN
PARTIAL NEPHRECTOMY
Open partial nephrectomy is more complex than radical
nephrectomy, and many authors place limits on its use citing
a higher risk of complications. Several decades ago, reports
o no p e nP Nd e s c r i b e dag r e a t e rr i s ko fa c u t er e n a lf a i l u r e ,
urinary ﬁstula, and hemorrhage of the surgical bed, among
other complications [15, 22, 35, 36].
The lower incidence of complications in the present
patient series can be attributed to the greater experience that
urologists have gained with this technique and the higher
prevalence of incidental small tumors. In 1994, Campbell
etal.[35] described complication rates after open PN of 37%
for symptomatic tumors and of 22% for incidental tumors
Table 2.
More recently, however, open PN and radical nephrec-
tomy have shown a similar complications’ rate, overall
morbidity rate, hospital stay, blood losses, and frequency of
a c u t er e n a lf a i l u r e[ 37, 38]. The risk of acute renal failure
after open PN ranges from 0 to 18% according to the series.
Campbell et al. [35] reported a 13% incidence of acute
renal failure in 259 patients after open PN (for which only
10/259 patients [3.9%] had an elective indication). Risk
factors for postoperative acute renal failure were tumor size
>7cm, excision of more than half the renal parenchyma,
and ischemia >60 minutes. In patients with PN, the renal
parenchymal volume loss correlates best with the renal
function loss several months after surgery. Estimates of
volume loss may be useful for predicting postoperative renal
functionwhenplanningPNinpatientswithasolitarykidney
[6, 7, 39].
The risk of urinary ﬁstula after open PN ranges from
1.8 to 21%, and is lower in patients treated for a small
incidental tumor with elective indication. Campbell et al.
[35] described an increased risk of urinary ﬁstula in tumors
>4cm localized centrally or near the hilum in surgery
requiring reconstruction of the excretory tract.
To summarize, complications of open PN appear to
have been reduced to levels found with open radical
nephrectomy—thanks to the greater experience of surgical
teams with this technique. In the medium term, however,
at 6–12 months, open PN patients have a signiﬁcantly
lower serum creatinine level compared with laparoscopic
radical nephrectomy patients [40]. This information must
be explained to patients when they are informed about the
short-term and long-term risks of the two approaches.
7. FOLLOW-UP GUIDELINES AFTER OPEN
PARTIAL NEPHRECTOMY
Several clinical guidelines have been established for the
follow-up of patients after open PN, based on detailed
analysis of reported tumor recurrence patterns at specialized
centers (e.g., Cleveland Clinic).
Rates of local recurrence and metastatic progression vary
as a function of the tumor stage at surgery as follows:
T1N0M0: 0% local recurrence and 4.4% distant progression;
T2N0M0: 2% and 5.3%, respectively; T3aN0M0: 8.2%
and 11.5%, respectively; T3bN0M0: 10.6% and 14.9%,
respectively. Postoperative time periods associated with a
maximum incidence of local recurrence are between 6 and
24 months for T3 and T2 tumors and after 48 months for T1
tumors. Hence, the follow-up time and protocol are selected
according to the pathological stage at the time of the open
PN.
Novick and Campbell [2] proposed these follow-up
guidelines.
(1) Patients with T1N0M0 tumors have annual anamne-
sis, physical examination, and serology, with no need
for radiology during the ﬁrst year. No subsequent
systematic diagnostic imaging studies are required
due to the low risk of recurrence.
(2) Patients with T2N0M0 tumors have annual anamne-
sis,physicalexamination,chestX-ray,andabdominal
CT scan, with abdominal X-ray every 2 years.
(3) PatientswithT3N0M0tumorshaveanamnesis,phys-
ical examination, chest X-ray, and abdominal CT
every 6 months for 3 years and then annually.
In the long term, hyperﬁltration can cause renal injury
in these patients, especially if there has been >50% loss of
nephrons, with proteinuria, focal segmental glomeruloscle-
rosis, and progressive renal failure. Because proteinuria is the
ﬁrst change in this disorder, 24-hour urine proteins should
be determined annually in all patients with suspicion of
hyperﬁltration due to loss of renal parenchyma.
8. WHENTOPROPOSEOPENPARTIALNEPHRECTOMY
Based on the above reported data, clinical studies (Mayo
Clinic, Cleveland Clinic, UCLA, etc.), and our ownJ. M. Cozar and M. Tallada 7
experience, we can aﬃrm, in common with other authors
[1, 2], that open PN is now the gold standard treatment for
young and healthy patients with incidentally detected small
r e n a lt u m o r s( <4cm). It also represents an alternative to
radical nephrectomy in single-kidney patients or those with
bilateral tumors.
The presence of renal failure, diseases that predispose
towards renal failure, or genetic syndromes associated with
multifocality also shows indications for open PN versus
radical nephrectomy since, in small tumors, there are no dif-
ferences in disease-free survival, morbidity, or complication
rates between the techniques.
The current standard surgical technique for partial
nephrectomy is open partial nephrectomy. Only certain
highly specialized centers have gained suﬃcient experience
withlaparoscopicPNtominimizeitsrisksandcomplications
[40]. It remains a challenging technique, requiring a longer
period of warm renal ischemia, vein closure, and the diﬃcult
suturing of open vessels during tumor resection. In fact,
the laparoscopic approach has been associated with a higher
rate of complications, even in the best hands. Thus, Sharma
et al. reported intra- and postoperative complication rates of
5% and 11%, respectively, using laparoscopic PN, compared
with 0% and 2%, respectively, using open PN [39].
Although no studies have been published to date on
the long-term oncological eﬀectiveness of laparoscopic PN
[1], preliminary data indicate that it does not diﬀer from
that obtained with the open approach. In 2007, Gill et al.
[41] reported three-year cancer-speciﬁc survival rates of
99.3% in 771 patients treated with laparoscopic partial
nephrectomy and 99.2% in 1028 patients treated with open
partial nephrectomy. The same study conﬁrmed a shorter
surgery time (P < .0001), hospital stay (P < .0001), and
a lower blood loss (P < .0001) with laparoscopic partial
nephrectomy versus open partial nephrectomy, while intra-
operative complication rates were similar. Disadvantages
of laparoscopic versus open partial nephrectomy were the
signiﬁcantly longer ischemia time (P < .0001) and the more
frequent postoperative complications, especially urological
disorders (P < .0001).
Importantly,thelaparoscopicapproachisassociatedwith
a reduction in postoperative pain and a shorter recovery
period, posing surgeons and patients with a diﬃcult decision
between open and laparoscopic partial nephrectomies for a
small incidentally detected renal tumor.
Renal laparoscopy will continue to develop, and urol-
ogists will gain greater experience with the technique over
time. Thus, outcomes published by Gill et al. in 2007 were
superior to those obtained by the same author in 2003
[41, 42]. It should be taken into account that the study by
Gill et al. comparing laparoscopic nephrectomy with open
partial nephrectomy [41, 43] was not a randomized clinical
trial. In fact, most of the tumors selected for open partial
nephrectomy were >4cm, and all of them were centrally
localized single tumors (size up to 7cm) with a malignant
histology. These cases are technically more challenging and
carry a higher oncological risk, representing an important
selection bias. There is a need for a randomized clinical trial
to be undertaken to assess the risks and beneﬁts of each
approach. Nevertheless, there is an evident trend towards
a minimally invasive approach to renal tumor treatment,
and we can expect laparoscopic PN to develop in the near
future to a point where it can replace open PN as a standard
treatment for localized renal tumors.
At our center, we have treated 35 patients by conservative
surgery of the renal parenchyma over the past 14 years
(1993–2007), using open PN in 7 and enucleation in 28, with
biopsies of the renal bed when involvement of the surgical
margin was suspected. Indications were elective in 16 cases
(45.5%), absolute in 11 (31.5%), and relative in 8 (23%).
Mean size of tumors was 3.6cm (range of 1–9cm), with
peripheral localization in 22 patients (63%), mesorenal in
12 (34%), and multifocal (6 tumors) in 1 patient (3%).
ApplyingthetechniquedescribedaboveinSection 5,wehave
had no intraoperative complications. Postoperative com-
plications were renocutaneous ﬁstula (resolved by internal
derivation via ureteral catheter) and acute tubular necrosis
(renal function recovered after hemodialysis) in the same
single-kidney patient. After a median follow-up time of 69
months, we have observed one local recurrence (3%), which
was from enucleation and was excised. Three patients died
due to other causes and three were lost to the follow-up after
moving from the area. All followed-up patients are disease-
free and have creatinine levels similar to preoperative values.
Based on this experience, our group considers conserva-
tive renal surgery to be an alternative to radical surgery in
tumors <4cm or in larger tumors in single-kidney patients.
Our selection of partial nephrectomy or enucleation is based
on tumor localization and size. Thus, we prefer enucleation
in tumors in mesorenal location because of its lower
comorbidity versus PN. Our approach to peripheral tumors
dependsontheirsize.Weuseenucleationforsmalltumorsof
1–3cm,butwepreferpartialnephrectomy fortumors ≥4cm
or when there is any suspicion of positive margins.
9. CONCLUSIONS
Open PN has been shown to be a safe and eﬀective
surgical technique in patients with a localized renal tumor,
including patients with a normal contralateral kidney. We
have gained experience with this technique by applying it
to patients with an absolute indication, and we are now
increasinglyabletorecommendittopatientswithanelective
indication, based on its good oncological outcomes and
lower morbidity rates versus radical nephrectomy. Moreover,
the preservation of nephrons achieved with open partial
nephrectomy reduces the long-term risk of renal failure in
these patients. These beneﬁts outweigh any problems caused
by the follow-up required for these patients due to fears of
local recurrence, which will undoubtedly be more eﬀectively
detected at an earlier stage with new three-dimensional
imaging techniques.
Nowadays, open PN is the gold standard technique to
treat small renal masses, and all nonablative techniques must
pass the test of time to be considered equally eﬀective.
It is not ethical for patients to undergo radical surgery
just because urologists involved do not have adequate
experience with PN or have concerns about their capacity8 Advances in Urology
to manage its possible complications. Patients must be
clearly informed about the possibility of laparoscopic PN
in specialized centers. Patients should be involved in the
ﬁnal treatment decision and, when appropriate, referred
to centers with experience in open or laparoscopic partial
nephrectomies.
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